Predicted protein targets (top 8)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | AURKA | O14965 | 20/20 | 1.00 |
| ▸ | TEK | Q02763 | 20/20 | 1.00 |
| ▸ | AURKB | Q96GD4 | 18/20 | 1.00 |
| ▸ | PDGFRB | P09619 | 16/20 | 1.00 |
| ▸ | EGFR | P00533 | 16/20 | 1.00 |
| ▸ | ERBB2 | P04626 | 14/20 | 1.00 |
| ▸ | FLT4 | P35916 | 11/20 | 1.00 |
| ▸ | KDR | P35968 | 11/20 | 1.00 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL5259545 | 1.00 | AURKA (1.00) | AURKATEKAURKBPDGFRBEGFR | |
| SCHEMBL5261293 | 0.94 | AURKA (0.89) | AURKATEKAURKBPDGFRBEGFR | |
| SCHEMBL5262916 | 0.94 | AURKA (1.00) | AURKATEKAURKBPDGFRBEGFR | |
| SCHEMBL5263078 | 0.94 | AURKA (1.00) | AURKATEKAURKBPDGFRBEGFR | |
| SCHEMBL5256644 | 0.92 | AURKA (1.00) | AURKATEKAURKBPDGFRBEGFR | |
| SCHEMBL5262194 | 0.92 | AURKA (1.00) | AURKATEKAURKBPDGFRBEGFR | |
| SCHEMBL5263573 | 0.92 | AURKA (1.00) | AURKATEKAURKBPDGFRBEGFR | |
| SCHEMBL5257166 | 0.91 | AURKA (1.00) | AURKATEKAURKBPDGFRBEGFR | |
| SCHEMBL5260719 | 0.91 | AURKA (1.00) | AURKATEKAURKBPDGFRBEGFR | |
| SCHEMBL5261158 | 0.90 | AURKA (0.90) | AURKATEKAURKBPDGFRBEGFR |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 5 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| WO-2007009524-A1 | 2-ARYLBENZOTHIAZOLES AND USES THEREOF | 4SC AG (DE) | 2007-01-25 | — | — | WO | disclosed |
| US-20070021446-A1 | 2-arylbenzothiazole analogues and uses thereof | 4SC AG (DE) | 2007-01-25 | — | — | US | disclosed |
| US-20070021446-A1 | 2-arylbenzothiazole analogues and uses thereof | 4SC AG (DE) | 2007-01-25 | — | — | US | disclosed |
| EP-1746096-A1 | 2-Arylbenzothiazole analogues and uses thereof in the treatment of cancer | 4SC AG (DE) | 2007-01-24 | — | — | EP | disclosed |
| EP-1746096-A1 | 2-Arylbenzothiazole analogues and uses thereof in the treatment of cancer | 4SC AG (DE) | 2007-01-24 | — | — | EP | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20070021446-A1 | 2-arylbenzothiazole analogues and uses thereof | NR2E1, NR2E3, NR0B2 | AURKA 493/4885TEK 1814/4885AURKB 300/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.